8-K filing — Evolution Metals & Technologies Corp. (EMAT)
Filed: 2026-10-15 AccNo: 0001213900-26-109622 Size: 500 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge
U.S. stocks fell Friday as weak industrial data weighed; Dow slid 0.45%, materials lagged, energy rose, and European shares declined.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Evolution Metals & Technologies Receives Additional Magnet Equipment From ULVAC At Its Pohang Facility And Expects Remainder This Month; Reaffirms FY27 Revenue Guidance Of $400M-$460M
Evolution Metals & Technologies Reaffirms FY27 Sales Guidance Of $400M-$460M; Expects To Begin Acquiring Equipment To Produce Samarium Cobalt Magnets By Mid-2027; Confirms Will Respond To U.S. Army’s Sources Sought Notice For Rare Earth Magnets
Evolution Metals & Technologies Corp. ("EM&T" or the "Company") (NASDAQ:EMAT), a U.S.-based critical materials and advanced manufacturing company, today announced that its portfolio of eight
EMAT stock has given up its prior gain. Evolution Metals & Technologies shares were trading higher after the company announced it raised its fiscal 2026 revenue guidance to $10 million to $11 million, up from the previous range of $5 million to $8 million announced on September 10, 2026.
Deal Dispatch: Jana Calls For Six Flags Review, Cognex Corp Buys RealSense, Brightline Bankruptcy
Major M&A deals this week include: Ridgeline Roofing buys Advantage Rooging, Forge buys Becker's Healthcare.
MISTR to Fund 2 Million Free HIV & Hepatitis C Tests and Help States Save Hundreds of Millions in ADAP Costs
MISTR, a telehealth platform for sexual health, announced a national commitment to provide 2 million free HIV and Hepatitis C tests by end of 2027 and introduced a partnership model to help states save hundreds of millions in AIDS Drug Assistance Program (ADAP) costs. The company will provide free PrEP to those testing negative for HIV and connect those testing positive to long-term care at no cost to patients or states.